Table 3.

All-grade treatment-emergent AEs within 8 weeks after first TACE and those with a frequency ≥10% in either group corresponding to grades 3 and 4

Adverse event, n (%)	TACE plus sorafenib (n = 77)				TACE alone (n = 71)
	all grades	grades 1–2	grade 3	grade 4	all grades	grades 1–2	grade 3	grade 4
Elevated AST	72 (93.5)	50 (64.9)	17 (22.1)	5 (6.5)	65 (91.5)	50 (70.4)	14 (19.7)	1 (1.4)
Elevated ALT	69 (89.6)	50 (64.9)	18 (23.4)	1 (1.3)	55 (77.5)	42 (59.2)	13 (18.3)	0 (0.0)
Thrombocytopenia	67 (87.0)	57 (74.0)	10 (13.0)	0 (0.0)	53 (74.6)	51 (71.8)	2 (2.8)	0 (0.0)
Elevated bilirubin	55 (71.4)	54 (70.1)	1 (1.3)	0 (0.0)	39 (54.9)	37 (52.1)	2 (2.8)	0 (0.0)
Anemia	50 (64.9)	49 (63.6)	1 (1.3)	0 (0.0)	35 (49.3)	34 (47.9)	1 (1.4)	0 (0.0)
Hand-foot skin reaction	51 (66.2)	47 (61.0)	4 (5.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension	45 (58.4)	37 (48.1)	8 (10.4)	0 (0.0)	28 (39.4)	25 (35.2)	3 (4.2)	0 (0.0)
Elevated lipase	38 (49.4)	26 (33.8)	11 (14.3)	1 (1.3)	18 (25.4)	16 (22.5)	2 (2.8)	0 (0.0)
Elevated serum amylase	32 (41.6)	26 (33.8)	6 (7.8)	0 (0.0)	19 (26.8)	18 (25.4)	1 (1.4)	0 (0.0)
Neutropenia	30 (39.0)	26 (33.8)	4 (5.2)	0 (0.0)	29 (40.8)	29 (40.8)	0 (0.0)	0 (0.0)
Decreased WBC count	29 (37.7)	28 (36.4)	1 (1.3)	0 (0.0)	26 (36.6)	26 (36.6)	0 (0.0)	0 (0.0)
Malaise	20 (26.0)	20 (26.0)	0 (0.0)	0 (0.0)	9 (12.7)	9 (12.7)	0 (0.0)	0 (0.0)
Fatigue	20 (26.0)	18 (23.4)	2 (2.6)	0 (0.0)	7 (9.9)	7 (9.9)	0 (0.0)	0 (0.0)
Fever	15 (19.5)	14 (18.2)	1 (1.3)	0 (0.0)	18 (25.4)	18 (25.4)	0 (0.0)	0 (0.0)
Anorexia	11 (14.3)	9 (11.7)	2 (2.6)	0 (0.0)	8 (11.3)	7 (9.9)	1 (1.4)	0 (0.0)
Diarrhea	13 (16.9)	11 (14.3)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Erythema multiforme	9 (11.7)	7 (9.1)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Weight loss	10 (13.0)	10 (13.0)	0 (0.0)	0 (0.0)	2 (2.8)	2 (2.8)	0 (0.0)	0 (0.0)
Hoarseness	10 (13.0)	10 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

ALT, alanine transaminase; AST, aspartate transaminase; WBC, white blood cell.